UNSPSC 51293606: Ciclazindol

This classification denotes an antidepressant agent with the molecular formula C17H15ClN2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Y3I9520J7P, chemically known as 10-(m-chlorophenyl)-2,3,4,10-tetrahydropyrimido(1,2-a)indol-10-ol but generally known as ciclazindol, which bears US NIH Compound Identifier 37825. European Medicines Agency schedules Ciclazindol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06235MIG.

UNSPSC 51293606 Ciclazindol is a Commodity code that in practice covers state and local procurement of pharmaceutical products, including naloxone, drug deactivation systems, generic multi-source pharmaceuticals, and over-the-counter products distributed through established supply chains and wholesaler networks. State and local governments soliciting under this code span county health departments, state health and human services agencies, and multistate cooperative purchasing alliances that aggregate demand across jurisdictions. The scope of work ranges from direct procurement of emergency medical countermeasures (such as naloxone for community health initiatives) to strategic sourcing of generic pharmaceuticals through authorized distributors, with vendors required to demonstrate FDA compliance, current Good Manufacturing Practices certification, Drug Supply Chain Security Act adherence, and established relationships with primary pharmaceutical wholesalers.

Recent activity reflects both direct county-level acquisitions and cooperative purchasing arrangements. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a two-year initial term; the Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather market intelligence on direct-to-manufacturer prescription programs prior to formal procurement; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products across participating state and local facilities in Minnesota and Oregon, with proposals due March 26, 2026 and contract effectiveness July 1, 2026. The code sees activity across the Southeast and Midwest, with multistate cooperative vehicles creating opportunities for vendors serving aggregated demand across multiple jurisdictions.